Generic name: hydroxychloroquine sulfate tablets.
Product name: Lefan
Hanyu pinyin: strong filter tablets with six acids
Main ingredients The main ingredient of this product is hydroxychloroquine sulfate.
Indications: lupus erythematosus, systemic lupus erythematosus and discoid lupus erythematosus.
Function Indications This product is used to treat discoid lupus erythematosus and systemic lupus erythematosus.
Usage and dosage: adult 0.4g daily, min 1 ~ 2 times. Depending on the patient's response, the dose can last for weeks or months. Long-term maintenance treatment, a small dose of 0.2g~0.4g per day is enough.
Specification 0. 1g
Adverse reactions 4-aminoquinoline compounds may have the following reactions during long-term treatment, but the types and incidence of adverse reactions of different compounds may be different. 1. Central nervous system reaction: excitement, tension, mood change, nightmare, psychosis, headache, dizziness, dizziness, tinnitus, nystagmus, nervous deafness, convulsion and ataxia. 2. Neuromuscular reaction: extraocular muscle paralysis, skeletal muscle weakness, and deep tendon reflex disappeared or decreased. 3. Eye reaction: 1 ciliary body: accommodation disorder with blurred vision. The reaction was dose-dependent and reversible after drug withdrawal. Cornea: transient edema, punctate to linear opacity, decreased corneal sensitivity. Common reversible visual blur, halo and photophobia corneal changes with or without symptoms. Corneal deposition may have appeared as early as 3 weeks after starting treatment. The incidence of corneal changes and visual side effects in hydroxychloroquine seems to be much lower than chloroquine. Retina: macular edema, atrophy, abnormal pigmentation, mild pigmentation, "bull's-eye" appearance, fovea reflex disappeared, after exposure to strong light load test, the recovery time of macula was prolonged, and the retinal threshold of macula, paramacula and peripheral retinal area for red light increased. Other fundus changes include pallor and atrophy of optic papilla, narrowing of retinal arterioles, disorder of fine pigment around retina, and late appearance of raised choroid. Visual field defect: there are blind spots around or near the center, central blind spots with decreased vision, and narrow visual field are rare. The most common visual symptoms attributed to retinopathy are: difficulty in reading and seeing, omission of words, letters or certain objects, photophobia, blurred hyperopia, disappearance or blackening of central or peripheral visual field, flashing and scribing. Retinopathy seems to be dose-related, which occurs after/kloc-0 treatment every day and lasts for several months to several years. A few years after antimalarial drug treatment stopped, a few cases were reported. 4-aminoquinoline compounds were used to treat malaria, with a weekly dose of 1 time. No retinopathy was found after long-term application. Patients with retinal changes may have visual symptoms or no symptoms with or without visual field changes, and may also have rare blind spots or visual field defects without obvious retinal changes. Retinopathy will progress even after drug withdrawal. There are many patients with early retinopathy and macular pigmentation, sometimes accompanied by central and visual field defects, which completely disappear or relieve after stopping treatment. Sometimes it is said that the central and lateral blind spots of the red target are signs of early retinal dysfunction, which is usually reversible after drug withdrawal. A few cases of retinal changes, reported to have occurred in patients who only received hydroxychloroquine's treatment, usually include retinal pigmentation changes found in regular eye examinations, and some cases still have visual field defects. It is reported that 65,438+0 cases of delayed retinopathy with visual loss occurred after hydroxychloroquine was stopped. 4. Skin reaction: hair whitening, alopecia, itching, pigmentation of skin mucosa, rash urticaria, measles-like, mossy-like, maculopapular rash, purpura, concentric annular erythema, exfoliative dermatitis. 5. Hematological reactions: such as hemolysis of patients with aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia and glucose -6- phosphate dehydrogenase G-6-PD deficiency. 6. Gastrointestinal reactions: loss of appetite, nausea, vomiting, diarrhea and abdominal cramps. 7. Others: weight loss, burnout, deterioration or acceleration of porphyria, non-photosensitive psoriasis. Rare myocardial diseases have been reported locally, but the relationship between them and hydroxychloroquine is not clear.
Taboo 1. Patients with retinal or visual field changes caused by 4-aminoquinoline compound therapy are prohibited. 2. Patients who are known to be allergic to 4-aminoquinoline compounds are prohibited.
Precautions 1. This product should be kept out of the reach of children. 2. Both patients with psoriasis and patients with porphyria will aggravate the original disease. Therefore, this product should not be used for these patients, unless according to the doctor's judgment, the benefits of patients will exceed their possible risks. 3. Doctors should be fully familiar with all the contents of this manual before prescribing this product. 4. Some patients who received long-term or high-dose treatment observed irreversible retinal damage, and it was reported that retinopathy was dose-related. 5. After taking this product, you should have an initial baseline and 1 eye examination every 3 months, including visual acuity, output slit lamp, ophthalmoscope and visual field examination. 6. If there are any abnormal signs in vision, visual field or macular area of retina, such as pigment change, loss of fovea reflex or any visual symptoms, such as flashing and streaking, which can't be completely explained by difficulty in adjustment or corneal opacity, stop taking medicine immediately and closely observe its possible progress. Even if the treatment is stopped, retinal changes and visual impairment may continue to develop. 7. All patients who use this product for a long time should be followed up and examined regularly, including knee and ankle reflexes, and find any signs of muscle weakness. If muscle weakness is found, the drug should be stopped. 8. Patients with liver disease or alcoholism, or when combined with drugs known to have hepatotoxicity, should be used with caution. 9. Patients who take this product for a long time should have blood cell count regularly. If there is any serious blood disease that cannot be attributed to the disease being treated, you should consider stopping taking this medicine. Patients who lack G-6-PD glucose -6- phosphate dehydrogenase should use this drug with caution. 10. Skin reaction may occur after taking this product. Therefore, if any patient receiving the drug has obvious tendency to develop dermatitis, it should be paid enough attention. 1 1. The recommended methods for early diagnosis of "hydroxychloroquine's sulfate retinopathy" are: 1 Check the macula with ophthalmoscope to see if there is slight pigment disorder or loss of foveal reflex. 2 Check whether there is a blind spot in the center of the visual field or around the central atrium with a small red marker, or determine the red retinal threshold. Any unexplained visual symptoms, such as flashing or streaking, should also be suspected as possible manifestations of retinopathy. 12. When severe poisoning symptoms occur due to overdose or allergy, it is recommended that adults take ammonium chloride orally, 8g a day, in batches, for 3 or 4 days a week, and continue to use it for several months after stopping taking the drug, because urine acidification can increase the renal excretion of 4-aminoquinoline compounds by 20% ~ 90%, but patients with renal function injury and/or metabolic acidosis should use it with caution.
Drug treatment for pregnant and lactating women is not clear.
Drug interactions are not clear.
Approval number: National Medicine Zhunzi H 19990263
Shanghai chinese and western medicine co., ltd.